Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21-Reference-Cited by-同舟云学术

Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21

Published:2015-06-29 Issue:1 Volume:96 Page:46-54
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Nahi Hareth¹,Våtsveen Thea Kristin²³,Lund Johan¹,Heeg Bart M.S.⁴⁵,Preiss Birgitte⁶,Alici Evren¹,Møller Michael Boe⁶,Wader Karin Fahl²⁷,Møller Hanne E.H.⁶,Grøseth Lill Anny²⁸,Østergaard Brian⁹,Dai Hong Yan³,Holmberg Erik¹⁰,Gahrton Gösta¹,Waage Anders²⁸,Abildgaard Niels⁹

Affiliation:

1. Department of Medicine; Karolinska Institutet; Stockholm Sweden

2. KG Jebsen Center for Myeloma Research; Department of Cancer Research and Molecular Medicine; Norwegian University of Science and Technology; Trondheim Norway

3. Department of Pathology; St Olavs Hospital; Trondheim Norway

4. PharmacoEpidemiology & PharmacoEconomics (PE2); University of Groningen; Groningen The Netherlands

5. Department of Epidemiology; University Medical Center Groningen; Groningen The Netherlands

6. Department of Pathology; Odense University Hospital; Odense Denmark

7. Department of Oncology; St Olavs Hospital; Trondheim Norway

8. Department of Hematology; St Olavs Hospital; Trondheim Norway

9. Department of Hematology; Odense University Hospital; Odense Denmark

10. Department of Oncology; Institute of Clinical Sciences; Sahlgrenska Academy at University of Gothenburg; Gothenburg Sweden

Publisher

Wiley

Subject

Hematology,General Medicine